Clinical Trials Sponsored by Adlai Nortye Biopharma Co., Ltd.

Total 231 results

Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Huabo Biopharm Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Solid Tumor

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Gongwin Biopharm Co., Ltd.

Recruiting

A Study of PTS100 in Primary HCC Patients (OASES)

Hepatocellular Carcinoma

Taiwan
TOT Biopharm Co., Ltd.

Completed

TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

Efficacy

China
Huabo Biopharm Co., Ltd.

Completed

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of of HOT1030 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Huabo Biopharm Co., Ltd.

Completed

A Study of Injection HB0017 in Adult Healthy Volunteers

Healthy Subjects

New Zealand
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

Glutaric Acidemia Type I | Glutaric Aciduria Type I

China
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Shanghai Blueray Biopharma Co., Ltd.

Not yet recruiting

Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Advanced Cancer | Peripheral T Cell Lymphoma
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Advanced Solid Tumors | Relapsed Or Refractory Non-Hodgkin Lymphoma

China
Wuhan YZY Biopharma Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

NSCLC Stage IV | Malignant Pleural Effusions

China
Etern BioPharma (Shanghai) Co., Ltd

Not yet recruiting

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (FIRST)

Advanced Solid Tumor

United States
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma

Mucosal Melanoma

China
Etern BioPharma (Shanghai) Co., Ltd

Recruiting

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
RetroLead (Shanghai) BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

Human Immunodeficiency Virus-1 (HIV-1) Infection
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Advanced Malignancies

China
Eucure (Beijing) Biopharma Co., Ltd

Completed

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Cancer

Australia
Wuhan YZY Biopharma Co., Ltd.

Unknown

A Study of M701 (EpCAM and CD3) in Malignant Ascites

Cancer | Malignant Ascites

China
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

Healthy Adult Subjects

United States
Kylonova (Xiamen) Biopharma co., LTD.

Not yet recruiting

Single-ascending Dose Study of Kylo-11 in Healthy Subjects

Cardiovascular Diseases

China
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy

Bietti Crystalline Dystrophy

China
Etern BioPharma (Shanghai) Co., Ltd

Recruiting

FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors (FLIGHT)

Advanced Solid Tumor

China
Wuhan YZY Biopharma Co., Ltd.

Recruiting

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
I-Mab Biopharma Co. Ltd.

Recruiting

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Coherent Biopharma (Suzhou) Co., Ltd.

Recruiting

A Study of CBP-1018 in Patients With Advanced Solid Tumors

Solid Tumor

China
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety and Tolerability of TWP-201 in Healthy Female Subjects

Infertility

China
Shandong TheraWisdom Biopharma Co., Ltd.

Not yet recruiting

The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Coherent Biopharma (Suzhou) Co., Ltd.

Recruiting

A Study of CBP-1008 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Chung Mei Biopharma Co., Ltd

Not yet recruiting

Safety and Efficacy of DCB-BO1301 in Advanced Melanoma

Advanced Melanoma
Wuhan YZY Biopharma Co., Ltd.

Active, not recruiting

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Adenocarcinoma

China
Wuhan YZY Biopharma Co., Ltd.

Active, not recruiting

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Metastatic or Locally Advanced Solid Tumors

China
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Eucure (Beijing) Biopharma Co., Ltd

Active, not recruiting

A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers

Melanoma | Pancreatic Ductal Adenocarcinoma

United States, Australia
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 COVID-19

United States
Eucure (Beijing) Biopharma Co., Ltd

Withdrawn

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)

HCC | NSCLC Stage IV | NSCLC Stage IIIB

China, Australia, Taiwan, Armenia, Austria
I-Mab Biopharma Co. Ltd.

No longer available

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

Solid Tumor Metastatic Cancer Advanced Cancer
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

Australia
Kylonova (Xiamen) Biopharma co., LTD.

Recruiting

Dose Escalation Study of Kylo-0603 in Healthy Subjects

Nonalcoholic Steatohepatitis

China
Coherent Biopharma (Hefei) Co., Ltd.

Recruiting

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Cancer, Breast | Cancer of Pancreas | Cancer Colorectal | Cancer, Lung | Cancer of Esophagus

China, United States
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study

Hemophilia B
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients

Hemophilia B

China
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors

Solid Tumor

Australia
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China, Australia
I-Mab Biopharma Co. Ltd.

Recruiting

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Gastric Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Carcinoma

United States, China
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Advanced Melanoma | Advanced Urothelial Carcinoma

China

Clinical Trials Sponsored by Adlai Nortye Biopharma Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations